Consistently, based on a large-scale retrospective study, in-hospital use of ACE inhibitors/ARBs was associated with a lower risk of 28-day death among hospitalized patients with COVID-19 and coexisting hypertension, coronary artery disease and hypertension combined with coronary artery disease [19]. This evidence concerns the gene ACE and coronary artery disorder.